Vor Biopharma Inc.
VOR
$23.83
-$1.27-5.06%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 71.55% | 166.54% | 181.23% | 115.29% | 77.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -82.55% | 5.61% | 14.85% | 2.18% | 844.67% |
| Operating Income | 82.55% | -5.61% | -14.85% | -2.18% | -844.67% |
| Income Before Tax | 96.01% | -575.94% | 5,709.72% | -2,848.89% | -5,552.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 96.01% | -575.94% | 5,709.72% | -2,848.89% | -5,552.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 96.01% | -575.94% | 5,709.72% | -2,848.89% | -5,552.75% |
| EBIT | 82.55% | -5.61% | -14.85% | -2.18% | -844.67% |
| EBITDA | 82.44% | -8.21% | -18.04% | -5.32% | -866.58% |
| EPS Basic | 99.54% | 1.92% | 1,067.73% | -1,410.89% | -2,981.92% |
| Normalized Basic EPS | 99.54% | 1.92% | 1,065.40% | -1,412.82% | -2,981.96% |
| EPS Diluted | 99.54% | 1.92% | 1,067.73% | -1,410.89% | -2,981.92% |
| Normalized Diluted EPS | 99.54% | 1.92% | 1,065.40% | -1,412.82% | -2,981.96% |
| Average Basic Shares Outstanding | 766.99% | 589.15% | 479.67% | 95.17% | 83.41% |
| Average Diluted Shares Outstanding | 766.99% | 589.15% | 479.67% | 95.17% | 83.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |